Simponi, Cimzia REMS A Portent For Rest Of TNF Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Risk Evaluation and Mitigation Strategies for Centocor's Simponi and UCB's Cimzia offer a guide to how sponsors of other tumor necrosis factor inhibitors can be expected to educate physicians about the risk of invasive fungal infections, including histoplasmosis, associated with the class of medications.